IS2057B - Aðferðir og lyfjablöndur til að örva vöxt taugaþráða með því að nota efnasambönd sem eru næm fyrir FKBP12 í sambandi við taugavaxtarþætti - Google Patents

Aðferðir og lyfjablöndur til að örva vöxt taugaþráða með því að nota efnasambönd sem eru næm fyrir FKBP12 í sambandi við taugavaxtarþætti

Info

Publication number
IS2057B
IS2057B IS5032A IS5032A IS2057B IS 2057 B IS2057 B IS 2057B IS 5032 A IS5032 A IS 5032A IS 5032 A IS5032 A IS 5032A IS 2057 B IS2057 B IS 2057B
Authority
IS
Iceland
Prior art keywords
fkbp12
stimulate
association
sensitive
compounds
Prior art date
Application number
IS5032A
Other languages
English (en)
Icelandic (is)
Other versions
IS5032A (is
Inventor
E. Zelle Robert
Su Michael
Original Assignee
Vertex Pharmaceuticals Incorporated.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25009484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2057(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharmaceuticals Incorporated. filed Critical Vertex Pharmaceuticals Incorporated.
Publication of IS5032A publication Critical patent/IS5032A/is
Publication of IS2057B publication Critical patent/IS2057B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS5032A 1996-11-13 1999-04-21 Aðferðir og lyfjablöndur til að örva vöxt taugaþráða með því að nota efnasambönd sem eru næm fyrir FKBP12 í sambandi við taugavaxtarþætti IS2057B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/748,447 US5840736A (en) 1996-11-13 1996-11-13 Methods and compositions for stimulating neurite growth
PCT/US1997/020866 WO1998020891A1 (en) 1996-11-13 1997-11-13 Methods and compositions for stimulating neurite growth using compounds with affinity for fkbp12 in combination with neurotrophic factors

Publications (2)

Publication Number Publication Date
IS5032A IS5032A (is) 1999-04-21
IS2057B true IS2057B (is) 2005-10-14

Family

ID=25009484

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5032A IS2057B (is) 1996-11-13 1999-04-21 Aðferðir og lyfjablöndur til að örva vöxt taugaþráða með því að nota efnasambönd sem eru næm fyrir FKBP12 í sambandi við taugavaxtarþætti

Country Status (32)

Country Link
US (3) US5840736A (OSRAM)
EP (1) EP0946190B1 (OSRAM)
JP (1) JP2001504470A (OSRAM)
KR (1) KR100544451B1 (OSRAM)
CN (1) CN1168442C (OSRAM)
AP (1) AP9901518A0 (OSRAM)
AR (1) AR011278A1 (OSRAM)
AT (1) ATE250424T1 (OSRAM)
AU (1) AU724833B2 (OSRAM)
BG (1) BG64670B1 (OSRAM)
BR (1) BR9712765A (OSRAM)
CA (1) CA2270634A1 (OSRAM)
CO (1) CO4930260A1 (OSRAM)
CZ (1) CZ296058B6 (OSRAM)
DE (1) DE69725169T2 (OSRAM)
DK (1) DK0946190T3 (OSRAM)
EA (1) EA004247B1 (OSRAM)
ES (1) ES2206753T3 (OSRAM)
HU (1) HU226728B1 (OSRAM)
IL (1) IL129555A (OSRAM)
IN (1) IN183740B (OSRAM)
IS (1) IS2057B (OSRAM)
NO (1) NO328030B1 (OSRAM)
NZ (1) NZ335394A (OSRAM)
PL (1) PL190903B1 (OSRAM)
PT (1) PT946190E (OSRAM)
SK (1) SK284535B6 (OSRAM)
TR (1) TR199901034T2 (OSRAM)
TW (1) TW513302B (OSRAM)
UA (1) UA63926C2 (OSRAM)
WO (1) WO1998020891A1 (OSRAM)
ZA (1) ZA9710256B (OSRAM)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5780484A (en) * 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US6242468B1 (en) 1997-02-27 2001-06-05 Jia-He Li Carbamate and urea compositions and neurotrophic uses
US6514686B2 (en) 1997-04-28 2003-02-04 The University Of British Columbia Method and composition for modulating amyloidosis
US5945441A (en) 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
US20010049381A1 (en) 1997-06-04 2001-12-06 Gpl Nil Holdings, Inc., Pyrrolidine derivative hair growth compositions and uses
US6852496B1 (en) * 1997-08-12 2005-02-08 Oregon Health And Science University Methods of screening for agents that promote nerve cell growth
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
EA200001247A1 (ru) 1998-06-03 2001-08-27 Джи Пи Ай Нил Холдингс, Инк. N-связанные сульфонамиды n-гетероциклических карбоновых кислот или изостеры карбоновых кислот
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
SK462001A3 (en) 1998-07-17 2002-02-05 Agouron Pharma Compounds, compositions, and methods for stimulating neuronal growth and elongation
GB9815880D0 (en) 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6395758B1 (en) 1998-08-14 2002-05-28 Gpi Nil Holdings, Inc. Small molecule carbamates or ureas for vision and memory disorders
US6462072B1 (en) 1998-09-21 2002-10-08 Gpi Nil Holdings, Inc. Cyclic ester or amide derivatives
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6228872B1 (en) 1998-11-12 2001-05-08 Bristol-Myers Squibb Company Neurotrophic diamide and carbamate agents
AU2173400A (en) * 1998-12-09 2000-06-26 Chiron Corporation Method for administering agents to the central nervous system
WO2000040557A1 (en) * 1999-01-08 2000-07-13 Vertex Pharmaceuticals Incorporated Process for the formation of intermediates useful for the preparation of pharmaceuticals
AU6073300A (en) 1999-07-06 2001-01-22 Vertex Pharmaceuticals Incorporated N-heterocyclic derivatives with neuronal activity
US6734211B1 (en) * 1999-07-09 2004-05-11 Oregon Health & Sciences University Compositions and methods for promoting nerve regeneration
JP2003505508A (ja) * 1999-07-30 2003-02-12 バーテックス ファーマシューティカルズ インコーポレイテッド 非環式又は環式アミド誘導体
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
BR0015486A (pt) * 1999-11-12 2002-07-02 Alcon Inc Ligandos de neurofilina para tratamento de condições oculares
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
US6818643B1 (en) 1999-12-08 2004-11-16 Bristol-Myers Squibb Company Neurotrophic bicyclic diamides
US7060676B2 (en) 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
WO2001046195A1 (en) 1999-12-21 2001-06-28 Gpi Nil Holdings, Inc. Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
US6555573B2 (en) 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
EP1575477B1 (en) * 2001-05-25 2012-04-25 Cornell Research Foundation, Inc. HIGH AFFINITY LIGAND FOR p75 NEUROTROPHIN RECEPTOR
EP1404325A2 (en) * 2001-05-29 2004-04-07 Guilford Pharmaceuticals Inc. Method for treating nerve injury caused by surgery
FR2825273B1 (fr) * 2001-05-29 2006-11-24 Oreal Composition pour le traitement des signes cutanes du vieillissement
US7435725B2 (en) * 2001-11-06 2008-10-14 The Quigly Corporation Oral compositions and methods for prevention, reduction and treatment of radiation injury
US20030118536A1 (en) * 2001-11-06 2003-06-26 Rosenbloom Richard A. Topical compositions and methods for treatment of adverse effects of ionizing radiation
US20030105027A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
US7232798B2 (en) 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
US20100247483A1 (en) * 2001-11-13 2010-09-30 Tran Loi H Therapeutic agent composition and method of use
WO2003041655A2 (en) * 2001-11-13 2003-05-22 Loi Tran Therapeutic agent composition and method of use
US7083813B2 (en) * 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
US8841326B2 (en) 2004-02-12 2014-09-23 Stc.Unm Therapeutic curcumin derivatives
US7935342B2 (en) * 2006-02-02 2011-05-03 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkB antagonist
NL2000464C2 (nl) * 2006-02-02 2007-09-11 Rinat Neuroscience Corp Werkwijzen voor het behandelen van ongewenst gewichtsverlies of eetstoornissen door het toedienen van een TRKB-agonist.
CN101605556A (zh) * 2006-12-20 2009-12-16 瑞纳神经科学公司 治疗自体免疫疾病的trkb激动剂
US20090018151A1 (en) * 2007-02-23 2009-01-15 Ezekiel Fink Topical Treatment of Peripheral diabetic complications
US11090303B2 (en) 2018-05-15 2021-08-17 Lloyd Hung Loi Tran Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798355A (en) 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
US5543423A (en) * 1994-11-16 1996-08-06 Vertex Pharmaceuticals, Incorporated Amino acid derivatives with improved multi-drug resistance activity
IL115685A (en) * 1994-11-16 2000-08-31 Vertex Pharma Amino acid derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5614547A (en) * 1995-06-07 1997-03-25 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US6037370A (en) * 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5801197A (en) * 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US5811434A (en) * 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
CN104718162B (zh) * 2012-09-28 2017-11-21 Dic株式会社 α‑氧化铝微粒以及其制造方法

Also Published As

Publication number Publication date
BR9712765A (pt) 1999-10-26
WO1998020891A1 (en) 1998-05-22
US6284778B1 (en) 2001-09-04
KR100544451B1 (ko) 2006-01-24
AP9901518A0 (en) 1999-06-30
NO328030B1 (no) 2009-11-16
AU5258998A (en) 1998-06-03
BG103429A (en) 2000-04-28
HK1022851A1 (en) 2000-08-25
TW513302B (en) 2002-12-11
ATE250424T1 (de) 2003-10-15
DE69725169T2 (de) 2004-07-15
NO992138L (no) 1999-07-13
TR199901034T2 (xx) 1999-07-21
IN183740B (OSRAM) 2000-04-01
IL129555A0 (en) 2000-02-29
CZ168399A3 (cs) 1999-08-11
UA63926C2 (uk) 2004-02-16
BG64670B1 (bg) 2005-11-30
IS5032A (is) 1999-04-21
EA199900464A1 (ru) 2000-02-28
ZA9710256B (en) 1998-05-28
PL333270A1 (en) 1999-11-22
DE69725169D1 (de) 2003-10-30
NZ335394A (en) 2000-06-23
HUP0001219A3 (en) 2001-12-28
PT946190E (pt) 2004-02-27
ES2206753T3 (es) 2004-05-16
US5840736A (en) 1998-11-24
HU226728B1 (en) 2009-08-28
CN1239433A (zh) 1999-12-22
EA004247B1 (ru) 2004-02-26
CA2270634A1 (en) 1998-05-22
KR20000068962A (ko) 2000-11-25
JP2001504470A (ja) 2001-04-03
AU724833B2 (en) 2000-09-28
PL190903B1 (pl) 2006-02-28
CZ296058B6 (cs) 2006-01-11
EP0946190A1 (en) 1999-10-06
HUP0001219A2 (hu) 2000-11-28
IL129555A (en) 2005-08-31
AR011278A1 (es) 2000-08-16
CN1168442C (zh) 2004-09-29
CO4930260A1 (es) 2000-06-27
NO992138D0 (no) 1999-05-03
DK0946190T3 (da) 2003-12-08
SK62899A3 (en) 2000-04-10
EP0946190B1 (en) 2003-09-24
US6172086B1 (en) 2001-01-09
SK284535B6 (sk) 2005-06-02

Similar Documents

Publication Publication Date Title
IS2057B (is) Aðferðir og lyfjablöndur til að örva vöxt taugaþráða með því að nota efnasambönd sem eru næm fyrir FKBP12 í sambandi við taugavaxtarþætti
NO20006604D0 (no) Fremgangsmåter og transdermale sammensetninger for lindring av smerte
NO994506D0 (no) FremgangsmÕter og blandinger for Õ modulere mottagelighet for kortikosteroider
DE19782118T1 (de) Photovoltaische Vorrichtung und ihr Vorbereitungsverfahren
DE69434666D1 (de) Vorrichtung zur elektrischen nervenstimulation
NO942193D0 (no) Metallocener og fremgangsmåte til deres fremstilling og bruk
DE69734300D1 (de) Vorrichtung zum Aufbewahren und Auftragen
DE69413930D1 (de) Hilfsmittel zur Verringerung der Fleckenbildung in photothermographischen und thermographischen Elementen
IS5044A (is) Aðferð og ný efnasambönd til að nota með henni
FI950465A7 (fi) Läpäisevä laastari lääkityksen antamiseksi ihoon
DE69728057D1 (de) Iontophoretische auslösbare lieferungsvorrichtung zur verminderung von elektrischen empfindungen
EE9800459A (et) Spiro-piperidiini derivaadid ja nende kasutamine terapeutiliste toimeainetena
IL127189A0 (en) Compositions methods and devices for the transdermal delivery of drugs
FI961855L (fi) Hermostojärjestelmään kuuluvien kantasolujen manipulointi ja modifiointi
PL325956A1 (en) Application of 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonylaminobenzene in prophylaxis and treatment of the effects of encephalitis and chronic encephalaemia as well as degenerative nervous system affections
DE69708738D1 (de) Vorrichtung zum Ausgleich von Momentschwankungen
FI912512A7 (fi) Laite tekohampaiden tukemiseksi leukaan ja menetelmä sen valmistamisek si
DE69622001D1 (de) Vorrichtung zum Setzen und Eindrehen von Schrauben
ATE217518T1 (de) Verwendung mindestens eines in 6-stellung substituierten pyrimidin-3-oxids zur stimulierung von tyrosinase
NO984836L (no) Substituerte benzylaminer og deres anvendelse for behandling av depresjon
IS4628A (is) Frumuröð sem myndar kvalastillandi efni til nota í meðferð gegn sársauka
DE69712502D1 (de) Vorrichtung zur stimulation der herzfunktion
DK521489A (da) Desacetoxycephalosporin c synthase i oprenset form og fremgangsmaade til fremstilling af dette enzym
GB2286613B (en) Improvements in or relating to methods and apparatus for improving the condition of ground
NO980396L (no) Börste med forbedret bustknipperetensjon og forankringsstreng for dette